Sources.

Primary medicine information

FDA prescribing information for Wegovy (semaglutide), revised August 2025

U.S. prescribing information for Zepbound (tirzepatide), revised April 2026

MedlinePlus: Semaglutide injection

Nutrition and symptom guidance

Cleveland Clinic: GLP-1 diet overview

Cleveland Clinic: Foods and GI side effects

Harvard Health: Managing GLP-1 side effects

Guy's and St Thomas' NHS: GLP-1 agonist medicines for diabetes

Cambridge University Hospitals: Tirzepatide patient guidance

Manufacturer symptom-management guidance

Eli Lilly: Zepbound nausea guidance, including smaller meals, stopping at fullness, limiting fatty foods, and trying bland foods

Novo Nordisk: General nausea tips for Wegovy, including bland lower-fat foods, water-containing foods, slower eating, and avoiding lying down after meals

How to interpret the database

The database translates general published guidance into practical food-level categories. It is not a clinical guideline, and the ratings do not replace individualized guidance from a prescriber or registered dietitian.

Last evidence review: June 11, 2026.

Image credits

Homepage food photography by Peggy Greb, U.S. Department of Agriculture, and Keith Weller, USDA Agricultural Research Service. The source images are public-domain works accessed through Wikimedia Commons. Images were cropped and compressed for web presentation.